and 25% had hyperleukocytosis. 2 patients had already taken antibiotics before admission. Group 2 included 13 patients, their mean PCT was 0.025 ng/mL (0.01-0.13), mean CRP was 132.25 mg/L, mean ESR was 84.38 mm, and 30.77% of them had hyperleukocytosis. Group 3 included 3 patients, their mean median CRP was 66.87 mg/mL (0.02-200), mean CRP was 560 mg/L, mean ESR was 107.33 mm, and 33.33% had hyperleukocytosis. The patient with the highest PCT was admitted for a sepsis with uricemic encephalopathy that improved after hemodialysis. A control PCT was made in 2 patients with infection who received antibiotics, showing a decrease or negativization compared to the initial value of PCT.

Conclusion: Our study showed that PCT levels only increased significantly in bacterial infections. The PCT values were more discriminating than the level of WBC and CRP in differentiating a bacterial infection from another inflammatory process, hence the value of using this marker in case diagnosis doubt.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3191

POS1368 ANTI-IL-1 THERAPIES IN COLCHICINE-RESISTANT OR INTOLERANT PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: SINGLE CENTER EXPERIENCE

M. E. Derin1, B. Karakaya2, B. Karataş3, N. Çalışkan Celik4, I. Yalçın5, A. Sahin6,
1Sivas Numune Hospital, Internal Medicine – Rheumatology, Sivas, Turkey;
2Sivas Cumhuriyet University, Internal Medicine – Rheumatology, Sivas, Turkey.

Background: Familial Mediterranean Fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation (1). The goal of FMF treatment is to prevent the attacks and to minimize subclinical inflammation between attacks. The main treatment of FMF is colchicine however anti-interleukin-1 treatments are recommended in colchicine-resistant and/or intolerant FMF patients (2).

Objectives: The aim of this study is to evaluate the efficacy of anti-interleukin-1 (anti-IL-1) agents in 81 FMF patients with resistant/intolerated to colchicine or complicated with amyloidosis.

Methods: Between January 2014 and December 2020, eighty-one patients who were diagnosed as FMF according to the criteria of Tel-Hashomer that following-up at Cumhuriyet University Medical Faculty Rheumatology-Internal Medicine Department were included in the study.

Results: 45 (55.6%) male and 36 (44.4%) female were included in the study. The median age of the patients was 25 years (min:17-max: 60) and the median age at diagnosis was 15 years (min:3-max: 46), 44 patients (54.3%) used Anakinra (100mg/day), and 27 (45.7%) canakinumab (150mg/8months) were used. 49 cases were resistant to colchicine, 16 were intolerant to colchicine, 16 (20%) cases were complicated with amyloidosis. MEFV gene mutations are shown in Table 1. Median duration of anti-IL-1 agent use was 24 months (min:4-max: 52). 9 patients were resistant to anakinra, 18 patients were resistant to canakinumab. Five pregnant patients were followed up with anakinra during pregnancy and there were no problems.

Conclusion: Anti-interleukin-1 agents are effectively and safely in the treatment of FMF patients. There are still unanswered questions in FMF treatment such as other factors affecting the frequency of attacks, colchicine resistance is not defined precisely and the importance of some mutations. The effect of anti-IL-1 agents on FMF patients with amyloidosis is not clearly. According to our experience, these treatments are effective in patients with glomerular filtration rate 60 ml/min. For answers to these and similar questions, Large and long follow-up studies are needed for long-term effects.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3257

POS1369 ADULT-ONSET STILL’S DISEASE: A SINGLE-CENTER EXPERIENCE

B. Eksi1, S. Uğurlu2, 1Boston Children’s Hospital, Immunology, Boston, United States of America; 2Istanbul University-Cerrahpasa, Internal Medicine, Istanbul, Turkey

Background: Adult-Onset Still’s disease (AOSD) is an autoinflammatory condition characterized by fever, rash, and arthritis. The diagnosis of AOSD is made by excluding common causes of fever of unknown origin which are infections, malignancies, autoimmune conditions and medication adverse effects. As it is a diagnostic challenge, further data on highlighting clinical and laboratory findings are necessary on guiding clinicians.

Objectives: Our main objective is to present our single tertiary center experience of patients diagnosed with AOSD.

Methods: This retrospective study was conducted at a tertiary rheumatology center. Patients were diagnosed with AOSD using Yamaguchi’s criteria and followed between 2007 and 2020. Demographic, clinical and laboratory information was retrieved from the patient charts. Treatment-related and prognostic information were also noted with additional information from phone call interviews.

Results: The study includes 69 patients (23 M, 46 F). The mean age of diagnosis was 33.6±14.3. The presenting signs and symptoms of the patients are shown in Figure 1. The laboratory findings supporting the diagnosis at initial encounter are summarized in Table 1. The mean corticosteroid dose at initial diagnosis was 29.7±18mg. In addition to corticosteroid treatment these patients were followed with different glucocorticoid-sparring agents. Methotrexate was the choice of treatment in 54 patients with the mean dose of 14.5±3.43 mg. Eight patients were treated with leflunomide, seven with anti-TNF agents, seven with tocilizumab, nineteen with anakinra and four with canakinumab.

Figure 1. The presenting signs and symptoms of the patients

Conclusion: In conclusion, the most common presenting symptoms in our AOSD cohort were fever and salmon-colored rash. In the differential diagnosis of fever of unknown origin especially with rash, AOSD should be considered. Corticosteroid was the main treatment modality. In patients who are unresponsive to conventional immunosuppressive treatment, biologic agents can be an alternative.

Table 1. The laboratory findings at initial encounter

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean ± Standard Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferritin (ng/mL)</td>
<td>3179.46±6503.56</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>77.43±28.47</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>102.29±70.39</td>
</tr>
<tr>
<td>Leukocyte Count (cells/L)</td>
<td>13147.3±4640.9</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>80±28.48</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>105.1±54.67</td>
</tr>
<tr>
<td>Leukocyte Count (cells/L)</td>
<td>12427.14±6530.43</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3380

POS1370 HYDROXYCHLOROQUINE-INDUCED ATRIOVENTRICULAR BLOCK IN IMMUNE-MEDIATED DISEASES. SINGLE UNIVERSITY CENTER STUDY OF 293 PATIENTS

A. Herrero-Morant1, A. Margarida-de Castro1, R. Pérez-Barquin1, J. Zubiaur-Zamaco1, M. Á. González-Gay1, R. Blanco1 1Hospital Universitario Marqués de Valdecilla, Rheumatology and Cardiology, Santander, Spain.

Background: Hydroxychloroquine (HCQ) is an extensively used drug in immune-mediated diseases (IMID). Despite its general safety, HCQ can cause serious toxicity such as heart conduction disorders. Atrioventricular block (AVB)